Medical technology industry expert Dr Greg Roger has been appointed by the federal government as the Supplier Advocate for the growing medical technologies market. [ + ]

Innovation Minister Senator Kim Carr yesterday opened a new $25 million imaging and medical beamline (IMBL), which will offer high-resolution, phase-contrast X-ray imaging of biomedical samples and a wide range of engineering materials. [ + ]

Biotron (ASX:BIT) has signed up the 12th and final subject for a phase II open-label trial of BIT225 in patients co-infected with - and receiving treatment for - HIV and HCV. [ + ]

A new WHO centre for chronic diseases has been established in Sydney. [ + ]

An onsite helium recovery system will make helium use more sustainable and help this finite resource be retained. [ + ]

Gtech International Resources, subsidiary of Genetic Technologies, has moved to acquire Simavita Holdings. [ + ]

An increased risk of Non-Hodgkin’s lymphoma (NHL) has been observed in recent years among individuals with occupational exposure to benzene, a chemical carcinogen linked to blood cancers. A study released in the journal Cancer set out to determine the risk of NHL for those living near benzene release sites. [ + ]

Applications are now open for the annual AusBiotech Student Volunteer Program at AusBiotech’s national conference, this year to be held in Brisbane (30 October-1 November). [ + ]

Consegna (ASX:CGP) has chosen ChinaMed as its global manufacturing partner for Turbine, a nasal dilator product bound for the Australian sporting goods market. [ + ]

Plastic surgeons have completed treatment for the last of 10 patients enrolled in a trial of PolyNovo’s NovoSorb BTM in free-flap donor site repair surgery. [ + ]

Bionomics (ASX:BNO) has launched IND-enabling pharmacology and toxicology studies for BNC101, its anticancer antibody candidate. [ + ]

You can register now to attend Australia Biotech Invest where you will hear world-leading biotech innovators and Australia’s investment community discuss the future of biotech in the Antipodes. [ + ]

Geneva-based Campus Biotech is open to Australian biotech companies interested in establishing offices of R&D facilities in Europe. [ + ]

Recruitment has begun for Invion’s phase II trial that aims to repurpose nadolol as a treatment for smoking cessation. [ + ]

Peptide drug discovery company Phylogica (ASX: PYC) is collaborating with US-based Cubist Pharmaceuticals (NASDAQ: CBST) to evaluate several of its antimicrobial Phylomers in models of multidrug-resistant bacterial infections. [ + ]